Statins and Cancer
Nov 19 2026
Edited and approved by Stephen C. Rose, PhD, MS
Statins are prescribed to lower LDL cholesterol and reduce the risk of heart attack and stroke. Their possible connection to cancer raises a different set of questions. Could lowering cholesterol increase cancer risk? Could the same medicines help prevent tumors or improve survival after diagnosis? The answers depend on which question we ask and what kind of evidence supports it. [1]
The most reliable evidence is reassuring about overall cancer safety. Evidence that statins prevent or treat cancer is less settled. Laboratory findings explain why researchers remain interested, but an effect inside a cancer cell is only the beginning of the case for treating a person. [2]
What randomized trials tell us about cancer risk
The Cholesterol Treatment Trialists’ Collaboration analyzed individual records from approximately 175,000 participants in 27 randomized trials. Over roughly five years, statin treatment did not measurably increase or decrease overall cancer diagnoses or cancer deaths. In trials comparing statins with control treatment, new cancers occurred at approximately 1.4% per year in both groups. More intensive cholesterol lowering also showed no overall cancer signal. [2]
That is stronger evidence than simply observing that people with lower cholesterol develop different illnesses. Random assignment makes treatment groups more comparable at the outset. The analysis argues against a substantial overall cancer hazard during the period studied; it also provides no basis for prescribing statins as general cancer prevention. Five years, however, cannot settle every question about rare cancers or effects that take decades to emerge. [2]
Longer follow-up adds reassurance. The West of Scotland Coronary Prevention Study originally randomized 6,595 men with elevated cholesterol to pravastatin or placebo for about five years. Across 20 years of follow-up, investigators found no increase in overall cancer incidence and no difference in cancer deaths between the original groups. Survival improved mainly through fewer cardiovascular deaths. [3]
This was not 20 years of continuously randomized treatment. Medication use changed after the trial, and researchers lacked statin-use information for the final decade. Even with that limitation, the findings support a practical longevity distinction: preventing cardiovascular disease can help people live longer without demonstrating an anticancer effect. [3]
Why cancer researchers study a cholesterol medicine
Statins block an enzyme called HMG-CoA reductase, which helps drive the mevalonate pathway, a series of chemical reactions inside cells. That pathway supplies cholesterol, but it also produces molecules involved in positioning and activating cellular signaling proteins. Interrupting it can therefore affect more than a cholesterol measurement on a blood test. [4]
A 2024 study explored one such connection. In experimental cells and mice, pitavastatin interrupted signaling that promotes production of interleukin-33, an immune messenger involved in certain forms of chronic inflammation. It suppressed inflammation-associated pancreatic cancer development in mice. Patient records also showed an association between pitavastatin use and lower pancreatic cancer risk, but that comparison was observational. It did not establish prevention in humans. [4]
The biological details matter. The investigators could reverse key cellular effects by restoring a mevalonate-pathway product called GGPP, but not by adding cholesterol. That experiment suggests a mechanism involving cellular signaling rather than simply a lower cholesterol concentration. It does not imply that suppressing the same pathway will benefit every cancer. [4]
Research published in 2026 illustrates a more specific possibility. Scientists studied non-small cell lung cancer models that had become resistant to drugs targeting a mutation called KRAS G12C. These resistant cells increased activity in the mevalonate pathway. Combining simvastatin with the targeted drugs improved tumor control and delayed resistance in experimental models. [5]
This is preliminary treatment research, not evidence that patients should add simvastatin themselves. The investigators specifically noted that their experimental dosing might not translate directly to humans. A treatment must reach the relevant tumor at a tolerable dose and improve meaningful outcomes, not merely interfere with a pathway in a laboratory. [5]
Promising findings in breast and liver cancer
Observational studies help identify settings worth testing. A 2025 Danish study used records from 66,952 women with early breast cancer to emulate a clinical trial of starting statins after diagnosis. Estimated ten-year breast cancer mortality was 11.8% among statin initiators and 13.5% among noninitiators, a difference of 1.7 percentage points. [6]
That difference is potentially important, but it remains an association. A “target trial emulation” uses study-design and statistical methods to make an observational comparison resemble a trial. It cannot create random assignment or recover information that was never measured. The researchers lacked data on factors including body mass index, physical activity, and diet, leaving room for residual confounding: other differences that could partly explain the result. [6]
A separate 2025 study examined 16,501 adults with chronic liver disease and elevated scores on a blood-based fibrosis assessment. Statin users had a lower estimated ten-year incidence of hepatocellular carcinoma, the most common primary liver cancer: 3.8% versus 8.0%. The association persisted after statistical adjustment. [7]
These were patients with existing liver disease, not a general-population screening sample. Differences in liver disease severity, prescribing decisions, and other care can influence comparisons between users and nonusers. The result supports a prevention hypothesis for a defined risk group; it does not establish that everyone should take a statin to avoid liver cancer. [7]
Across these studies, the question also changes. Avoiding a first cancer, preventing recurrence after treatment, and improving survival with an established tumor are separate outcomes. A favorable result for one cannot automatically answer the others. When reading a headline, identifying the population and the actual outcome is as important as noticing the size of the reported benefit.
What happens when the treatment is tested directly
The LUNGSTAR trial provides a useful caution. Investigators randomly assigned 846 people with small-cell lung cancer to chemotherapy plus either pravastatin or placebo. Adding pravastatin did not improve survival. Median survival was 10.7 months with pravastatin and 10.6 months with placebo, and the overall survival comparison showed no benefit. [8]
This does not exclude a role for a different statin in a different tumor or treatment combination. It does show why promising biology and favorable observational findings are insufficient to establish a broadly effective cancer treatment. Small-cell lung cancer in LUNGSTAR and the KRAS-mutant non-small cell models are different diseases studied with different drugs and methods. Their findings should not be treated as interchangeable. [8] [5]
The MASTER trial was designed to test another setting. Its published protocol describes randomizing women with early, estrogen receptor-positive breast cancer to standard treatment plus atorvastatin or placebo for two years. Its main outcome is invasive disease-free survival, which tracks events such as invasive recurrence or death. The 2025 publication describes the trial design, not evidence that atorvastatin has already improved those outcomes. [9]
What this means for patients now
For someone already taking a statin because of cardiovascular risk, the cancer evidence offers reassurance. Continuing treatment should depend on its established indication, tolerability, other illnesses, and the overall care plan. A cancer diagnosis is a reason to review medicines with the oncology team and prescribing clinician, rather than assume that a cardiovascular medicine has become unnecessary. [1]
Statins are not free of adverse effects. They can increase diabetes risk, particularly in people already susceptible, and occasionally cause muscle problems or abnormal liver tests. Other medicines and supplements can interact with them. Those considerations become especially relevant when several treatments are being used together. Do not stop, increase, or switch a prescribed statin on the strength of a cancer headline. [1]
For cancer prevention or treatment alone, the evidence reviewed here does not justify starting a statin outside a clinician-directed research or treatment plan. The next useful advance would be a reproducible benefit in a clearly defined patient group, with an appropriate drug, dose, and safety assessment. Until then, the established cardiovascular benefit and the investigational cancer possibilities should remain distinct when making treatment decisions.
References
[1] National Library of Medicine. Statins. MedlinePlus. Updated May 5, 2025. Accessed September 25, 2026.
[2] Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e29849. doi:10.1371/journal.pone.0029849.
[3] Ford I, Murray H, McCowan C, et al. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073-1080. doi:10.1161/circulationaha.115.019014.
[4] Park JH, Mortaja M, Son HG, et al. Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression. Nat Commun. 2024;15(1):4099. doi:10.1038/s41467-024-48441-8.
[5] Lin W, Chen QA, Yang Y, et al. Targeting the mevalonate pathway with statins overcomes acquired resistance to KRASG12C inhibitors in non-small cell lung cancer. Exp Hematol Oncol. 2026;15(1):52. doi:10.1186/s40164-026-00797-x.
[6] Harborg S, Pedersen L, Sørensen HT, et al. Postdiagnosis Statin Use and Breast Cancer Mortality. JAMA Netw Open. 2025;8(10):e2538737. doi:10.1001/jamanetworkopen.2025.38737.
[7] Choi J, Nguyen VH, Przybyszewski E, et al. Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease. JAMA Intern Med. 2025;185(5):522-530. doi:10.1001/jamainternmed.2025.0115.
[8] Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506-1514. doi:10.1200/jco.2016.69.7391.
[9] Borgquist S, Jensen MB, Bendorff CL, et al. Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo. Clin Epidemiol. 2025;17:409-419. doi:10.2147/clep.s509873.
Scientific & Medical Editorial Standards
Content published by LongevityWiz is developed and reviewed by qualified scientific and medical professionals, including experts holding doctorates in Bioengineering and Immunology and a physician who is a Fellow of the American College of Cardiology (FACC). Our editorial approach emphasizes scientific accuracy, peer-reviewed research, and evidence-based health information. Content is provided for educational purposes only and does not constitute individualized medical advice. Read our full Medical Disclaimer. LongevityWiz does not provide personalized healthcare guidance. Always consult a physician or other qualified healthcare professional before changing your diet, exercise routine, medications, supplements or overall healthcare plan. Never disregard professional medical advice or delay seeking treatment because of information you have read on this website.
